Related Experiment Video

Updated: Sep 27, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

Peptide mimotopes of oncoproteins as therapeutic agents in breast cancer

B T Ashok1, L David, Y G Chen

  • 1Department of Microbiology and Immunology and Medicine, New York Medical College, Valhalla, NY 10595, USA.

International Journal of Molecular Medicine
|March 13, 2003
PubMed

Insights

Synthetic peptides mimicking cancer-causing oncoproteins can generate immune responses. Researchers identified specific peptides that bind to HER-2/neu, validating their potential for cancer immunotherapy by eliciting tumor-specific immunity.

Area of Science:

  • Oncology
  • Immunology
  • Biotechnology

Background:

  • Oncoproteins can trigger cancer-specific immune responses, offering potential therapeutic targets.
  • HER-2/neu overexpression in breast cancer correlates with poor prognosis and increased metastasis.

Purpose of the Study:

  • To evaluate the clinical utility of synthetic peptides designed to mimic oncoprotein antigens.
  • To generate tumor-specific immune responses using synthetic peptides.

Main Methods:

  • Utilized phage display peptide libraries (LX-8 and X-15) to isolate peptides.
  • Screened peptides using antibodies (Ab2, Ab4, Ab5) against the HER-2/neu oncoprotein.
  • Sequenced and characterized isolated peptides for immunogenicity and cross-reactivity.

Main Results:

  • Identified synthetic peptides that mimic HER-2/neu antigenic epitopes without sequence homology to known proteins.
  • Demonstrated varying antibody affinities against peptides selected with the same antibody.
  • Showed that phages displaying selected peptides could inhibit antibody binding to HER-2/neu.

Conclusions:

  • Synthetic peptides can effectively mimic oncoprotein antigenic epitopes.
  • Clinical utility depends on screening mechanisms to identify peptides inducing effective anti-tumor immune responses.
  • Potential for developing immunotherapies targeting oncoproteins and their variants.

More Related Videos

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: